FindTrial
Sign In

A study to determine whether non-pharmacological methods like Hormetic stressors can be used in the treatment of knee osteoarthritis

The Effect of Hormetic Stressors on Knee Osteoarthritis- A Multicenter Randomized Control Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052202
Enrollment
200
Registered
2023-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Hormetic Stressors: The Hormetic protocol which will be tested will be as following- 1. Caloric restriction 6 days a week successively by using 18 hours fasting and 6 hour eating period

Sponsors

Dr Mahendra Suresh Sinai Kudchadker
Lead Sponsor
Dr Sandeep Shrivastava
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult in the age group of 40-70 years 2.Knee with KL (Kellgren Lawrence) grade II and III OA (Osteoarthritis).

Exclusion criteria

Exclusion criteria: 1.Grade 4 OA KNEE 2.Age younger than 40 yrs and Older than 70 yrs 3.Any prior surgical intervention or intraarticular injections in the past year - If patients did not follow atleast 2 of the 3 hormetic stressors for atleast for 6 weeks - Co-morbidities which are at risk for hormetic therapy- IHD, Vasovagal syncope, DM type 1 etc., - Other ipsilateral joint deformities effecting clinical intervention and true assessment of effected knee.

Design outcomes

Primary

MeasureTime frame
1.Pain: a.VAS score 2.Knee Functions: a.WOMAC Score b.Walking ability- 6 minute walk test c.Range of Motion of knee joint using Goniometer Timepoint: at day 1, 12 weeks and 16 weeks—

Secondary

MeasureTime frame
1. Serum Inflammatory markers like ESR, CRP & IL6 and 2. Synovial thickness whether nodular or diffuse, and effusion measured in suprapatellar and lateral and medial recesses using B mode multi frequency (7-12hz) linear array transducer Ultrasound in patients willing to do and consenting of their own accord. 3. MRI and CT scan for measurement of cartilage thickness in a few randomized patients 4. Leucocyte Telomere length in few random patients. Primary and secondary outcomes 1 and 2 will be mandatory while secondary outcome measure 3 and 4 will be optional in the study. Timepoint: at day 1, 12 weeks and 16 weeks—

Countries

India

Contacts

Public ContactDr Mahendra Suresh Sinai Kudchadker

Healthway Group of Hospitals

ortho67@gmail.com9822101506

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026